2024-03-29T10:33:52Z
https://soar-ir.repo.nii.ac.jp/oai
oai:soar-ir.repo.nii.ac.jp:00003895
2022-12-14T04:40:26Z
461:462
Rituximab therapy in nephrotic syndrome due to AH amyloidosis
Katoh, Nagaaki
Matsuda, Masayuki
Miyazaki, Daigo
Gono, Takahisa
Yazaki, Masahide
Ikeda, Shu-ichi
AH amyloidosis
nephrotic syndrome
B-cell lymphoproliferative disorder
rituximab
This is an electronic version of an article published in Amyloid 2009, Vol. 16, No. 3 : Pages 178-180. Amyloid is available online at: http://informahealthcare.com/doi/pdf/10.1080/13506120903090940
We report a patient with AH amyloidosis associated with lymphoplasmacytic leukemia that has remained in a stable state with a nephrotic syndrome for 17 months since the commencement of cyclic rituximab therapy aimed at suppression of pathogenetic gamma heavy chains. Free light chains in serum and CD20-positive cells in peripheral blood were useful as hematological markers in the patient. Rituximab might be a potent therapeutic option for AH amyloidosis associated with a B-cell lymphoproliferative disorder.
Article
AMYLOID. 16(3):178-180 (2009)
journal article
INFORMA HEALTHCARE
2009
application/pdf
Amyloid-Journal of Protein Folding Disorders
3
16
178
180
1350-6129
AA11096426
https://soar-ir.repo.nii.ac.jp/record/3895/files/Rituximab_therapy_nephrotic_syndrome.pdf
eng
19590993
https://pubmed.ncbi.nlm.nih.gov/19590993
10.1080/13506120903090940
https://doi.org/10.1080/13506120903090940